Overview
THERAtRAME discovers and develops first-in-class small molecules targeting tRNA epitranscriptomics for cancer patients. The company's proprietary platform targets tRNA modifications to develop therapies for immune-refractory and target-therapy resistant tumors. Their investment plan focuses on advancing their lead program into clinical development while strengthening their platform and biomarker capabilities.
Key people
Related profiles
Something wrong or missing? Send an update. Fixed within 24 hours.